June 12, 2020
Ono Pharmaceutical/Seikagaku’s investigational osteoarthritis drug diclofenac etalhyaluronate (ONO-5704/SI-613) smashed its primary target in a PIII study in Japan in patients with knee osteoarthritis, the companies revealed on June 11. In the PIII study, which enrolled 440 patients with knee osteoarthritis...read more